Sequence Information

    • DRAMP ID

    • DRAMP20774

    • Name

    • Murepavadin (POL7080)

    • Sequence

    • cyclo[Ala-Ser-D-Pro-Pro-Thr-Trp-Ile-Dab-Orn-D-Dab-Dab-Trp-Dab-Dab]

    • Description

    • synthetic by amino acid substitution of protegrin I.

    • Activity

    • Antibacterial

    • Target Organism

      • [Ref.29686157]Murepavadin (MIC50/90, 0.12/0.12 mg/liter) was 4- to 8-fold more active than colistin (MIC50/90, 1/1 mg/liter) and polymyxin B (MIC50/90, 0.5/1 mg/liter) and inhibited 99.1% of isolates at ≤0.5 mg/liter. Only 4 isolates (0.3%) exhibited murepavadin MICs of >2 mg/liter. Murepavadin was equally active against isolates from Europe, the United States, and China.

    • Reference

      • Antimicrobial Activity of Murepavadin Tested against Clinical Isolates of Pseudomonas aeruginosa from the United States, Europe, and China.(PMID: 29686157)
      • Murepavadin activity tested against contemporary (2016–17) clinical isolates of XDR Pseudomonas aeruginosa.(PMID: 29901750)
      • Cyclic peptide therapeutics: past, present and future.(PMID: 28249193)

Clinical Information

    • Medical use

    • Treatment of nosocomial pneumonia and ventilator-associated bacterial pneumonia (VABP)

    • Company

    • Polyphor Ltd.

    • Stage of Development

    • Phase III(suspended, adverse events)

    • Comments

    • This is a phase 3, multicenter, open-label, sponsor blinded, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability of intravenous murepavadin given with ertapenem versus an anti-pseudomonal β-lactam based antibiotic in the treatment of nosocomial pneumonia in adult subjects (ClinicalTrials.gov Identifier: NCT03582007). This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous murepavadin combined with of one anti-pseudononas antibiotic with that of two anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia (VABP) in adult subjects (ClinicalTrials.gov Identifier: NCT03409679).

    • Clinical Trials

    • NCT03409679
    • NCT03582007
    • NCT02096328